Insulet Corporation (NASDAQ:PODD) Given Average Recommendation of “Hold” by Brokerages

Insulet Corporation (NASDAQ:PODD) has received a consensus recommendation of “Hold” from the twenty-seven analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and fourteen have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $195.40.

Several research firms have recently weighed in on PODD. Leerink Partners cut Insulet from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. Stifel Nicolaus dropped their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Jefferies Financial Group reduced their target price on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. UBS Group decreased their price target on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Finally, William Blair assumed coverage on shares of Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating for the company.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, supported by strong demand for its Omnipod insulin-delivery system and improved margins. The earnings beat indicates that underlying demand and profitability remain healthy. PODD’s Q2 Earnings Top Estimates, FY’26 Sales View Cut
• Neutral Sentiment: Rosen, Faruqi & Faruqi, the DJS Law Group, Schall Brown & Schwartz, and the Law Offices of Howard G. Smith reminded investors of a pending securities class action and the August 31, 2026, deadline to seek lead-plaintiff status. The announcements largely repeat the same legal information and are not evidence that the claims have been proven. Faruqi & Faruqi Insulet Investor Reminder
• Negative Sentiment: Insulet reduced its fiscal 2026 revenue outlook despite beating quarterly estimates. The lowered sales forecast raises concerns about growth momentum and was identified as the main reason the stock remained under pressure after the earnings release. Insulet Q2 Earnings and Fiscal 2026 Outlook
• Negative Sentiment: Stifel, Benchmark, UBS, and TD Cowen all lowered their price targets to $180, $185, $150, and $144, respectively. JPMorgan reiterated a “Neutral” rating, while Wall Street Zen cut the stock to “Hold,” signaling more cautious expectations for PODD. Analyst Price Target Changes

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its position in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet in the fourth quarter worth approximately $26,000. Elyxium Wealth LLC bought a new stake in Insulet in the fourth quarter valued at approximately $28,000. DV Equities LLC bought a new stake in Insulet in the fourth quarter valued at approximately $28,000. Finally, MV Capital Management Inc. acquired a new stake in Insulet during the 4th quarter valued at approximately $29,000.

Insulet Trading Up 1.2%

NASDAQ PODD opened at $142.85 on Tuesday. The company has a market cap of $9.91 billion, a price-to-earnings ratio of 26.70, a price-to-earnings-growth ratio of 1.04 and a beta of 1.10. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The business’s fifty day moving average is $155.31 and its 200 day moving average is $191.94.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, sell-side analysts expect that Insulet will post 6.51 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.